Management of Bullous Pemphigoid and Norwegian Scabies with Dupilumab Plus Ivermectin.

Am J Trop Med HygSep 22, 2026 (epub)
Case ReportDermatologyOpen access

Yanli Zhang, Yuting Liu, Hengan Yi

✦ AI-curated · Sources linked

Case in brief

An elderly patient had bullous pemphigoid alongside Norwegian scabies, a rare comorbidity. Because systemic corticosteroids pose substantial risks in older patients, treatment began with a low-to-moderate corticosteroid dose. The patient then achieved complete remission with combination therapy using dupilumab, which targets interleukin-4/13 signaling, and ivermectin.

What made this case unusual

The case combined bullous pemphigoid with Norwegian scabies and achieved complete remission with dupilumab plus ivermectin after initial low-to-moderate-dose corticosteroid treatment.

Diagnostic / clinical pearl

When bullous pemphigoid coexists with Norwegian scabies in an elderly patient, this report describes remission after initial corticosteroid induction followed by dupilumab and ivermectin.

Why it matters

The case suggests a potential corticosteroid-sparing approach for this comorbidity in patients at high risk from systemic corticosteroids.

Source

Published in Am J Trop Med Hyg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Dermatology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.